These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9402746)

  • 1. Low-dose long-term oral idarubicin in maintenance treatment of elderly acute myeloid leukemia.
    Musso M; Porretto F; Crescimanno A; Bondì F; Polizzi V; Scalone R; Tolomeo M; Mariani G
    Haematologica; 1997; 82(5 Suppl):4-8. PubMed ID: 9402746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
    Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
    Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idarubicin in induction treatment of acute myeloid leukemia in the elderly.
    Leoni F; Ciolli S; Nozzoli C; Marrani C; Caporale R; Ferrini PR
    Haematologica; 1997; 82(5 Suppl):13-8. PubMed ID: 9402748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of chronic oral daily administration of idarubicin.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Rimondi G; Bearz A; Stocco F; Robieux I; Boiocchi M
    Haematologica; 1997; 82(5 Suppl):1-3. PubMed ID: 9402745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
    Ferrara F; Palmieri S; Annunziata M; Viola A; Pocali B; Califano C; D'Arco AM; Mele G
    Bone Marrow Transplant; 2004 Oct; 34(7):573-6. PubMed ID: 15258559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
    Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
    J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia.
    Ferrara F; Palmieri S; De Simone M; Sagristani M; Viola A; Pocali B; Fasanaro A; Mele G
    Br J Haematol; 2005 Jan; 128(2):234-41. PubMed ID: 15638859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy.
    Fiegl M; Büchner T; Hiddemann W; Braess J
    Ann Hematol; 2005 Apr; 84(4):227-31. PubMed ID: 15517268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
    Ferrara F; Palmieri S; Pedata M; Viola A; Izzo T; Criscuolo C; Mele G
    Hematol Oncol; 2009 Mar; 27(1):40-5. PubMed ID: 19206083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
    Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
    Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multi-institutional randomized controlled clinical trial on China made 4-demethoxydaunokrubicin (IDA) in the treatment of acute leukemia].
    Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lü JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
    Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):750-2. PubMed ID: 16483490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
    Ferrara F; Mele G; Palmieri S; Pedata M; Copia C; Riccardi C; Izzo T; Criscuolo C; Musto P
    Hematol Oncol; 2009 Dec; 27(4):198-202. PubMed ID: 19475701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
    Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.